1-4 of 4
Emanuela Cuomo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5353: PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

Ursula Grazini, Daniel J. O'Neill, Matthew Martin, Chintia Xu, Nicolas Floch, Paul D. Smith, Emanuela Cuomo
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5353.
https://doi.org/10.1158/1538-7445.AM2022-5353
Published: 15 June 2022
View articletitled, Abstract 5353: PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC
Journal Articles

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Jacqueline H. Starrett, Alexis A. Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg, Dylan Farnsworth, Kristin S. Price, Hina Khan, Kumar Dilip Ashtekar, Mmaserame Gaefele, Deborah Ayeni, Tyler F. Stewart, Alexandra Kuhlmann, Susan M. Kaech, Arun M. Unni, Robert Homer, William W. Lockwood, Franziska Michor, Sarah B. Goldberg, Mark A. Lemmon, Paul D. Smith, Darren A.E. Cross, Katerina Politi
Journal: Cancer Research
Cancer Res (2020) 80 (10): 2017–2030.
https://doi.org/10.1158/0008-5472.CAN-19-3819
Published: 15 May 2020
View articletitled, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Open the PDF for Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract 2079: Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR

Nicolas Floc'h, Susan Ashton, Ambra Bianco, Nicola Colclough, Darren AE Cross, Maria Emanuela Cuomo, M. Raymond V. Finlay, Matthew J Martin, Ludovic Menard, Darren McKerrecher, Daniel J O'Neill, Jonathan P Orme, Anna D Staniszewska, Richard A Ward, James W T Yates
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2079.
https://doi.org/10.1158/1538-7445.AM2017-2079
Published: 01 July 2017
View articletitled, Abstract 2079: Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR
Journal Articles

Antitumor Immune Effector Mechanisms Recruited by Phage Display-derived Fully Human IgG1 and IgA1 Monoclonal Antibodies

Gerwin Huls, Ingmar A. F. M. Heijnen, Emanuela Cuomo, Joke van der Linden, Edwin Boel, Jan G. J. van de Winkel, Ton Logtenberg
Journal: Cancer Research
Cancer Res (1999) 59 (22): 5778–5784.
Published: 01 November 1999
View articletitled, Antitumor Immune Effector Mechanisms Recruited by Phage Display-derived Fully Human IgG1 and IgA1 Monoclonal Antibodies
Open the PDF for Antitumor Immune Effector Mechanisms Recruited by Phage Display-derived Fully Human IgG1 and IgA1 Monoclonal Antibodies in another window